The global Wilson disease drugs market is expected to grow at a CAGR of 4.5% during the forecast period (2022-2028). Various strategies adopted by the key players and FDA-approved drugs for the treatment of Wilson’s disease are supporting the growth of the global Wilson disease drugs market. For instance, in May 2022, the US FDA approved Cuvrior for the treatment of stable Wilson diseases in adults, who are decoppered and tolerant to penicillamine. The Cuvrior contains trientine, a copper chelator that eliminates absorbed copper from the human body by forming a stable complex, which is eliminated from urine excretion. Cuvrior is supplied as a functionally scored tablet containing 300mg of trientine tetrahydrochloride. The product is expected to be available in early 2023.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/wilson-disease-drugs-market
Vivet Therapeutics and Pfizer announced the US FDA has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson’s disease in august 2021. VTX-801 is a novel investigational gene therapy, which is evaluated in a phase ½ clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the phase ½ clinical trial.
Further, in September 2019, the US FDA approved Kadmon Holdings, generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. The US FDA has determined that Kadmon’s Trientine hydrochloride capsules are bioequivalent to the listed drug, Syprine Capsules 250 mg.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2021-2028
- Segment Covered-
o By Drug Type
o By Route of Administration
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Bausch Health Co. Inc., Nobelpharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., and Kadmon Holdings, Inc.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Wilson Disease Drugs Market Report by Segment
By Drug Type
- Chelating Agents
- Zinc
- Tetrathiomolybdate
By Route of Administration
- Oral
- Parenteral
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
A full report of Wilson Disease Drugs Market is available at: https://www.omrglobal.com/industry-reports/wilson-disease-drugs-market
Wilson Disease Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca plc
- Deep Genomics
- DepYmed Inc.
- Reddy’s Laboratories Ltd.
- Lupin Ltd.
- Orphalan SA
- Pfizer Inc.
- Ultragenyx Pharmaceutical Inc.
- Vivet Therapeutics
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
